TY - GEN AU - Jihun Kim AU - Woong-Yang Park AU - Nayoung K D Kim AU - Se Jin Jang AU - Sung-Min Chun AU - Chang-Ohk Sung AU - Jene Choi AU - Young-Hyeh Ko AU - Yoon-La Choi AU - Hyo Sup Shim AU - Jae-Kyung Won AU - TI - Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests. PY - 2017/// CY - [Place of publication not identified] PB - Korean Society of Pathologists and Korean Society for Cytopathology KW - Neoplasms KW - Quality control KW - Molecular Pathology KW - Practice Guidelines As Topic KW - High-throughput Nucleotide Sequencing KW - B. Sc. Medical Laboratory Science KW - UMUN open access collection KW - laboratory quality KW - Review articles N1 - Publication type: Review article; Linked open-access copy: published version; Open access; no subscription required for the linked open-access version N2 - Next-generation sequencing (NGS) has recently emerged as an essential component of personalized cancer medicine due to its high throughput and low per-base cost. However, no sufficient guidelines for implementing NGS as a clinical molecular pathology test are established in Korea. To ensure clinical grade quality without inhibiting adoption of NGS, a taskforce team assembled by the Korean Society of Pathologists developed laboratory guidelines for NGS cancer panel testing procedures and requirements for clinical implementation of NGS. This consensus standard proposal consists of two parts: laboratory guidelines and requirements for clinical NGS laboratories. The laboratory guidelines part addressed several important issues across multistep NGS cancer panel tests including choice of gene panel and platform, sample handling, nucleic acid management, sample identity tracking, library preparation, sequencing, analysis and reporting. Requirements for clinical NGS tests were summarized in terms of documentation, validation, quality management, and other required written policies. Together with appropriate pathologist training and international laboratory standards, these laboratory standards would help molecular pathology laboratories to successfully implement NGS cancer panel tests in clinic. In this way, the oncology community would be able to help patients to benefit more from personalized cancer medicine UR - https://europepmc.org/articles/PMC5445206 ER -